Treatment of recurrent or metastatic non-nasopharyngeal squamous cell carcinoma of the head and neck (SCCHN) has remained relativ...
MARKET OUTLOOK NASH has the potential to be a large and lucrative therapy market owing to the prevalence of the disease...
MARKET OUTLOOK Pancreatic cancer is a life-threatening disease with a survival rate of less than 10% and with no improvements in the last 40 years...
MARKET OUTLOOK Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (
No disease-modifying therapies are approved to treat primary Sjögren’s syndrome (pSS), a progressive, autoimmune disease characterized b...
Over the past two decades, in response to mounting failures, clinical trials of disease-modifying therapies (DMTs) in Alzheimer’s disease (
MARKET OUTLOOK Renal inflammation associated with systemic lupus erythematosus (SLE), also known as lupus nephritis (
The management of pediatric patients with moderate to severe atopic dermatitis (AD) is poised for transformation. Sanofi/Regeneron’s Dupixent, on...
DED is one of the most common ocular conditions in the United States and Europe. Inflammation plays a prominent role in the pathogenesis of
Insomnia is a highly prevalent sleep disorder characterized by daytime dysfunction resulting from sleep problems. The treatment of insomnia is...
MARKET OUTLOOK Several effective anti-inflammatory agents and bronchodilators are available for controlling patients’ mild or moderate asthma...
Coming Soon – October 2019 MARKET OUTLOOK Rituximab-based chemoimmunotherapy regimens (e.g.,
MARKET OUTLOOK Although TNF-alpha inhibitors remain the preferred choice for psoriatic arthritis (
MARKET OUTLOOK Rheumatoid arthritis (RA) patients refractory to one or more TNF-&alp...
MARKET OUTLOOK Dyslipidemia is an important modifiable risk factor for CV disease and is primarily managed with statin therapy. Based...
MARKET OUTLOOK Multiple myeloma is an incurable hematological malignancy despite the availability of several treatment options. Resistance to...
Childhood absence epilepsy (CAE) is characterized by frequent and brief absence seizures in children aged 4-12 and is diagnosed in approximately 10...
MARKET OUTLOOK Treatment of moderate to severe Crohn’s disease (CD) typically begins with safe, albeit often less-efficacious,...
Get content updates to your inbox
Subscribe